Pacific Biosc Stock Price, News & Analysis

PacBio announced the launch of its Revio long-read sequencing system, designed to significantly enhance throughput and affordability of HiFi sequencing. Revio allows sequencing of up to 1,300 human genomes annually at 30-fold coverage for under $1,000 per genome. The system features a new SMRT Cell design with three-fold higher density, NVIDIA GPUs for enhanced computing power, and reduced consumable requirements. With a list price of $779,000, PacBio aims to deliver Revio in early 2023, empowering large studies across human genetics and agricultural genomics.

PacBio (NASDAQ: PACB) announced the external beta testing of its Onso™ sequencing system, a revolutionary benchtop short-read DNA sequencing platform known for its accuracy. This system, leveraging PacBio's proprietary SBB technology, is expected to enhance capabilities in oncology and disease research. Orders for Onso are anticipated in Q1 2023, with shipments commencing in H1 2023. The platform is designed for various library preparations and is priced at $259,000. Beta testing will occur at three prestigious sites, enabling feedback for further development.

PacBio (NASDAQ: PACB) announced the withdrawal of its 2022 financial guidance due to upcoming product announcements. The company will discuss its third quarter financial results during a conference call on November 7, 2022, and will also hold its inaugural Investor Day on November 15, 2022. These events will feature presentations from the executive team and Q&A sessions. Investors are encouraged to listen live via PacBio's website.

PacBio (NASDAQ: PACB) launched the innovative Multiplexed Arrays Sequencing (MAS-Seq) kit, developed in collaboration with the Broad Institute and 10x Genomics. This kit facilitates cost-effective, long-read single-cell RNA sequencing, enhancing research capabilities, particularly in cancer and neurodegenerative diseases. The MAS-Seq kit aims to identify novel isoforms and mutations and will be accompanied by new SMRTLink software for data analysis. Orders are being accepted, with shipments starting in early November. A webinar to discuss the technology is scheduled for November 16, 2022.

PacBio (NASDAQ: PACB) and Twist Bioscience have launched a new portfolio of long-read sequencing panels, including a 50-gene pharmacogenomics panel and a 400-gene 'dark gene' panel. Designed for cost-effective high-throughput sequencing, these panels target medically significant genes related to various diseases. The collaboration aims to enhance research capabilities in genetics, facilitating the understanding of drug response and disease mechanisms. Additionally, the technology promises greater accuracy in sequencing challenging genomic regions.

PacBio (NASDAQ: PACB) has launched the Consortium for Long Read Sequencing (CoLoRS) aimed at creating a publicly accessible database of human genome datasets using long-read sequencing technology. This initiative will support researchers in identifying genetic variations, particularly in rare diseases, where many cases remain unexplained. Funded by the National Institutes of Health, CoLoRS will house data processed through standardized pipelines and will be available via the NHGRI's cloud-based platform. The database is expected to be populated by late 2022.

PacBio (NASDAQ: PACB) announced a new computational analysis method called Tandem Repeat Genotyping Tool (TRGT) for studying tandem repeats (TRs) in the human genome. This tool enables comprehensive profiling of TRs and their methylation status, aiding researchers in understanding their role in diseases like ALS and Fragile X syndrome. TRGT improves the analysis of genetic variations and can identify disease-causing TRs. The tool is available on GitHub alongside a companion visualization tool, enhancing usability for genomic research.

PacBio (NASDAQ: PACB) will participate in the Morgan Stanley 20th Annual Global Healthcare Conference in New York on September 14 at 1:30 p.m. Eastern Time. A fireside chat with management will be accessible via a live webcast on the company's investor page. The event will conclude with a replay available for 30 days. PacBio is known for its advanced sequencing solutions, addressing complex genetic research across various applications, including oncology and infectious diseases. For more details, visit www.pacb.com.

PacBio (NASDAQ: PACB) announced the grant of non-qualified stock options covering 475,000 shares to its new Chief Commercial Officer, Jeff Eidel, under the Pacific Biosciences 2020 Inducement Equity Incentive Plan, effective August 16, 2022. The options have an exercise price of $8.00, which matches the closing stock price on the effective date. The vesting schedule includes 1/4 of the shares vesting after one year, followed by monthly vesting of 1/48 thereafter, contingent on Eidel’s continued service.